Philogen (http://www.philogen.com/) was founded in 1996 with the mission to develop new bio- pharmaceuticals for the treatment of angiogenesis-related disorders, such as cancer, rheumatoid arthritis and endometriosis. The company has been a pioneer in the isolation, engineering and clinical development of lead products capable of targeting angiogenesis in vivo and has been the first in the world to demonstrate that human monoclonal antibodies, specific for a marker of angiogenesis, can efficiently and selectively target the neo-vasculature in patients with cancer or with rheumatoid arthritis. At present, the company has four promising anti-cancer antibody derivatives and one antibody- derivative for the treatment of rheumatoid arthritis in >10 international clinical studies. Two registrational clinical trials are about to be launched. Philogen generates revenues from a diversified range of activities, has signed agreements with major pharmaceutical companies, has been granted over 100 valid national patents worldwide, and is cash-flow positive since 1999. Because of its extensive (and well documented) track record in taking lead products from the lab to Phase I / II clinical trials, Philogen is perfectly fit to accomplish the tasks required by the IMMUNOSABR project. Philogen staff is expert in the GMP production of immunocytokines, in the preparation and submission of dossier to competent authorities and in the management of clinical trials according to GCP.